SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices surge amid reported tanker attacks and supply risks around the Strait of Hormuz, alongside concerns about Saudi and Russian energy infrastructure. Traders are split between betting on further gains from geopolitical disruption and warning that prices look extended and could retreat if diplomacy or supply relief eases those fears.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure amid concerns about its heavy debt burden, expensive financing, and whether AI demand and backlog can generate sufficient returns; HSBCs bearish assessment has sharpened that debate. Bears warn of refinancing strain and possible dilution, while bulls point to contracted demand and argue the selloff is excessive, with dip buyers watching support levels.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO slide is being tied by traders to recurring lockup share releases and insider selling, alongside a TD Cowen rating-target cut and concerns about the AI-chip sector. The community is divided between expecting more downside amid valuation, customer-concentration, and scaling concerns, and viewing the selloff as an oversold opportunity based on Cerebras technology and potential demand.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock to Sell, citing lengthy commercialization timelines and a lack of firm customer commitments. The move has sharpened debate over execution risk and cash burn, with some traders viewing the selloff as a buying opportunity while others see limited commercial progress as a reason for caution.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers sharp selloff is being tied mainly to its convertible-note financing and debt conversion, which traders fear will dilute shareholders, alongside broader weakness in AI/data-center stocks and concerns about debt and execution. The community is split between calling the decline an oversold buying opportunity and warning that selling pressure could continue.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Morgan Stanleys upgrade of Amazon to a Top Pick, backed by expectations for accelerating AWS growth and AI-related demand, fueled a sharp rally. Traders welcomed the upgrade, though some questioned whether the move can hold and pointed to the upcoming earnings report as a test of the growth and spending outlook.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the recent AI-stock selloff has put QQQ in focus, but traders are divided over whether it marks a recovery or a short-lived relief rally and bull trap. Upcoming megacap earnings and lingering concerns about AI spending and debt, alongside rising oil prices, are adding to the volatility.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff across AI infrastructure and neocloud stocks, amid concerns about debt, financing costs, and returns on data-center spending, has driven NBIS discussion. Traders are split on whether the stocks rebound signals stabilization or a bull trap: bulls see Nebius as better positioned than more leveraged peers, while bears remain wary of funding needs and sector-wide risk.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops warrant-expiration deadline dominates discussion, with holders weighing whether the warrants can become exercisable against the risk they expire worthless. Traders disagree over whether the expiration would ease dilution concerns or signal a failed catalyst, while some speculate Ryan Cohen may extend the warrants or take action to lift the share price.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

Pre-earnings positioning is driving attention, with traders focused on GE Aerospaces Q3 report and what it may signal about engine demand, supply constraints, margins, and guidance. Views are split between dip buyers citing the companys backlog and demand and cautious traders pointing to the recent weakness and downside hedging.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.read more...

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind licenses Technosphere GLP-1 tech to Rose Pharma for weight management development.read more...

MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching

Equity

MannKind and Rose Pharma are partnering to develop an inhaled weight-loss treatment using the Technosphere dry-powder inhalation technology.

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.read more...

MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost  

FDA approved MannKind’s Furoscix ReadyFlow on Friday.

MNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism Builds 

The FDA is expected to announce its decision on MannKind’s sNDA on July 26, 2026.


MannKind Corporation (Nasdaq: MNKD) is a commercial-stage biopharmaceutical company with a diversified business spanning marketed products, strategic collaborations and a proprietary development pipeline. Focused on cardiometabolic and orphan lung diseases, MannKind’s portfolio includes Afrezza® (inhaled mealtime insulin), FUROSCIX® (furosemide injection for fluid overload) and V-Go® (all-in-one insulin delivery patch). Its proprietary Technosphere® technology is also utilized in Tyvaso DPI® (an inhaled treatment for pulmonary hypertension), marketed by United Therapeutics. The company is advancing additional inhaled therapies and drug-device combination products designed to address serious unmet medical needs. Founded by Alfred E. Mann in 1991, MannKind is headquartered in Danbury, Connecticut.

Mannkind Corp

Neutral Sentiment

<ul class="summary-bullets"><li>MannKind will help develop the formulation and provide manufacturing support through the completion of a Phase 1b study.</li><li>MannKind will receive an equity stake in Rose Pharma and potential royalties on future sales.</li><li>Financial terms of the agreement were not disclosed.</li></ul><p>The weight-loss drug market has been dominated by injectable GLP-1 therapies, but MannKind (MNKD) is looking at a different approach. MannKind (MNKD) is pushing into the booming GLP-1 weight-loss market, partnering with Rose Pharma to develop an inhaled treatment using its proprietary Technosphere dry-powder inhalation technology.</p><p><a href="https://stocktwits.com/symbol/MNKD">MNKD shares</a> were up 1.7% at the time of writing in pre-market, tracking a third straight session of gains.</p><h2 class="st-heading-2">What MannKind Gets From The Rose Pharma Deal&nbsp;</h2><p>MannKind and Rose Pharma said they will develop ROSE-010 Technosphere. MannKind will help develop the formulation and provide manufacturing support through the completion of a Phase 1b study.</p><p>In return, it will receive an equity stake in Rose Pharma and potential royalties on future sales. However, the agreement's financial terms were not disclosed.</p><h2>Why Rose Pharma’s ROSE-010 Matters</h2><p>ROSE-010 is designed as a rapid-acting, short-duration treatment. The drug itself has already been evaluated in four human studies. Rose said a previous Phase 2a weight-management study showed reduced calorie intake during meals and weight loss, along with favorable gastrointestinal tolerability.</p><p>“An inhaled therapy with a rapid-acting, short-duration profile could provide patients with greater flexibility and a new way to approach weight management. ROSE-010 Technosphere also has potential application in irritable bowel syndrome, where there is significant unmet medical need for pain relief,” said Enda Kenny, CEO of Rose Pharma.</p><h2 class="st-heading-2">MannKind Has Been Here Before&nbsp;</h2><p>The GLP-1 field isn’t entirely new to MannKind. More than 16 years ago, the company studied MKC253, an inhaled GLP-1 delivered using Technosphere. However, development was halted after a Phase 1 trial.</p><h2 class="st-heading-2">MannKind Builds On Recent Inhaled-Drug Win</h2><p>The deal also comes months after one of MannKind’s biggest recent regulatory victories.&nbsp; In May, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/mnkd-stock-jumps-on-receiving-fda-approval-for-afrezza-to-treat-diabetes-in-children/cZgSyurReMx">approved</a> the expanded use of MannKind’s inhaled insulin Afrezza to children and adolescents aged six and older with diabetes, making it the first and only inhaled mealtime insulin approved for that age group.</p><p>The approval was supported by the Phase 3 INHALE-1 study.</p><h2 class="st-heading-2">MNKD Stock: Retail Mood</h2><p>Meanwhile, retail sentiment surrounding MNKD remained ‘bearish’ over the past 24 hours.&nbsp;</p><p>The stock has shed more than 25% of its value so far in 2026.</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/equity/oil-traders-short-term-bets-iran-war-morgan-stanley-brent-100/cZt7RmsRJz2"><strong>Oil Traders Are Reportedly Cutting Back On Long-Term Bets As Iran, Ukraine Wars Rage, Morgan Stanley Says – ‘People Have Been More Precise With Their Risk’</strong></a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

MannKind Wants A Piece Of The Weight-Loss Market – But It’s Taking An Inhaled Route

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$3.09
Prev Close	$3.04
Open	$3.18
Dividend Yield	0.00%
50-Day Moving Average	$3.71
Beta	0.86
Avg. Volume	4.67M
PE Ratio	-21.81

52-Week High	$6.51
52-Week Low	$2.23
Market Capitalization	$977.5M
EPS (Annual)	$0.0187
Price to Book	-14.25
Revenue Per Employee	$589,469.59

Feed

News

Sentiment

Earnings

Fundamentals

Info

MNKD Fundamentals